Spinal Muscular Atrophy
By Yasser Salem. Encyclopedia of Behavioral Medicine, 2000
971 citations recorded by the source corpus.
Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder characterized by progressive muscle weakness. It has varying clinical severity, ranging from mild proximal muscle weakness to death from restrictive lung disease. The diagnosis is confirmed by genetic testing. Treatment includes survival motor neuron (SMN2) splicing modulator nusinersen, which may be challenging to administer intrathecally as patients develop varying degrees of scoliosis over time, making midline or paramedian lumbar punctures difficult. Patients with complex spinal anatomy may benefit from preprocedural and intraprocedural imaging to allow for a transforaminal approach for the intrathecal administration of nusinersen. Additional SMA treatments include risdiplam, a newer, oral splicing modulator, or SMN1 gene replacement therapy with Zolgensma.
Subfields: Genetics, Molecular Biology, Surgery
View Paper: https://www.semanticscholar.org/paper/d84fbcbb3b335aab28719597b387b53edcc85c09
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Molecular Biology
In Surgery
Citations in the corpus
- Chemistry, structure and function of approved oligonucleotide therapeutics (2023, background): “Infantile-onset SMA robs the individual of the ability to move, eat or breathe and was reported as the leading genetic cause of death for infants (257).”